Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
132.5 USD | -0.52% | -2.49% | +0.59% |
Apr. 17 | Nxera Pharma's Neuro Drug NBI-1117568 Passed Preclinical Toxicity Test | MT |
Apr. 16 | Neurocrine Biosciences, Sentia Medical Sciences Extend Partnership on Prospective Drug Development | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+0.59% | 13.33B | |
-3.30% | 102B | |
+1.79% | 96.07B | |
-1.92% | 21.66B | |
-18.35% | 20.77B | |
-8.86% | 18.53B | |
-40.31% | 16.91B | |
-26.84% | 13.79B | |
+20.86% | 10.94B | |
-21.69% | 8.57B |
- Stock Market
- Equities
- NBIX Stock
- News Neurocrine Biosciences, Inc.
- Neurocrine Biosciences Q3 Non-GAAP Earnings, Revenue Rise